Abstract
The purpose of this study was to evaluate a new type of tumor biomarker, eukaryotic elongation factor 2 (eEF2), in serum for the early diagnosis, confirmative diagnosis as well as assessment of treatment of non-small cell lung cancer (NSCLC). 130 patients with NSCLC and 50 healthy individuals undergoing physical examination in our hospital provided the observation and healthy control groups. An enzyme linked immune sorbent assay (ELISA) method was applied to determine serum eEF2 levels. Serum neuron specific enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group were assessed with an automatic biochemical analyzer. The median levels of eEF2 in the serum of NSCLC patients was found to be significantly higher than the healthy control group (p < 0.01) and it was markedly higher in stages III, IV than stages I, II (p < 0.05). eEF2 was higher with tumor size ≥ 2 cm than <2 cm (P< 0.01). Furthermore, two weeks after surgery patients showed a significant trend for eEF2 decrease (p < 0.05). The eukaryotic elongation factor 2 (eEF2) has certain clinical values for early diagnosis, verification, and prognosis as well as classification of lung cancer patients.
Highlights
Lung cancer is a heterogeneous disease with currently still unknown mechanisms of development (Massion et al, 2003)
Whereas patients had surgical operation two weeks later showed a significant trend of eukaryotic elongation factor 2 (eEF2) decrease whereas patients (Table 1)
The value of the eEF2, squamous cell carcinoma antigen (SCC), neuron specific enolase (NSE) in the lung cancer was evaluated with receiver operating characteristic (ROC) curve analysis the area under the curve (AUC) for the serum eEF2, SCC and NSE were 0.763, 0.671, and 0.702 (Figure 1)
Summary
Lung cancer is a heterogeneous disease with currently still unknown mechanisms of development (Massion et al, 2003). In 2012, there will be an estimated 226, 000 new cases of lung cancer diagnosed in this country and over 160, 000 individuals are expected to die from this disease (Siegel et al, 2012). The purpose of this study was to evaluate a new type of tumor biomarker, eukaryotic elongation factor 2 (eEF2), in serum for the early diagnosis, confirmative diagnosis as well as assessment of treatment of non-small cell lung cancer (NSCLC). Results: The median levels of eEF2 in the serum of NSCLC patients was found to be significantly higher than the healthy control group (p < 0.01) and it was markedly higher in stages III, IV than stages I, II (p < 0.05). Conclusions: The eukaryotic elongation factor 2 (eEF2) has certain clinical values for early diagnosis, verification, and prognosis as well as classification of lung cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
